Adverum Biotechnologies, Inc.

ADVM · NASDAQ
Analyze with AI
9/30/2025
6/30/2025
3/31/2025
12/31/2024
Operating Activities
Net Income-$47,652-$49,191-$47,019-$40,931
Dep. & Amort.$465$535$683$810
Deferred Tax$0$0$0$0
Stock-Based Comp.$2,349$2,423$2,778$0
Change in WC$16,647$7,490$215$8,932
Other Non-Cash$76-$24$572$2,940
Operating Cash Flow-$28,115-$38,767-$42,771-$28,249
Investing Activities
PP&E Inv.-$142-$120-$220-$61
Net Acquisitions$0$0$0$0
Inv. Purchases$0-$1,976$0-$19,128
Inv. Sales/Matur.$2,000$34,000$31,500$15,000
Other Inv. Act.$0$0$0$0
Investing Cash Flow$1,858$31,904$31,280-$4,189
Financing Activities
Debt Repay.$0$0$0$0
Stock Issued$9,899$120$0$239
Stock Repurch.$0$0$0$0
Dividends Paid$0$0$0$0
Other Fin. Act.$0$0$0$0
Financing Cash Flow$9,899$120$0$239
Forex Effect$0$0$0$0
Net Chg. in Cash-$16,358-$6,743-$11,491-$32,199
Supplemental Information
Beg. Cash$44,394$51,137$62,628$92,851
End Cash$28,036$44,394$51,137$60,652
Free Cash Flow-$28,257-$38,887-$42,991-$28,310
Adverum Biotechnologies, Inc. (ADVM) Financial Statements & Key Stats | AlphaPilot